AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
June 01, 2020- Submissions supported by two Phase 3 studies in which RINVOQ demonstrated improved joint outcomes, physical function and skin symptoms, with a greater proportion of patients achieving minimal disease activity versus placebo* [1,2]
-
June 01, 2020Connecting with patients to participate in device tracking enables them to be contacted in the event of a safety issue
-
May 29, 2020- Uterine fibroids are the most common type of benign tumor in women of reproductive age[1]
-
May 27, 2020- First presentation of the SELECT-CHOICE study evaluating efficacy and safety of RINVOQ™ (upadacitinib) compared to abatacept in patients with moderate to severe active rheumatoid arthritis
-
May 15, 2020- AbbVie to present more than 30 abstracts from studies of its on-market and investigational medicines from its oncology portfolio and pipeline across six tumor types at the EHA Annual Congress
-
May 08, 2020- Creates biopharmaceutical company with leadership positions in key therapeutic areas: Immunology, Hematologic Oncology, Neuroscience, and Allergan Aesthetics
-
May 01, 2020- Reports First-Quarter Diluted EPS of $2.02 on a GAAP Basis; Adjusted Diluted EPS of $2.42
-
April 21, 2020- IMBRUVICA plus rituximab demonstrated superior progression-free survival against the chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL)
-
April 02, 2020
-
March 31, 2020- AbbVie partners with International Medical Corps, Direct Relief and Feeding America to increase healthcare capacity, supply critical equipment and deliver food and essential supplies
-
March 23, 2020- VIALE-A study demonstrated statistically significant improvement in the primary endpoints of overall survival (OS) and composite complete remission rate (CR + CRi)
-
March 12, 2020- VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL)
-
March 09, 2020- Unconfirmed media reports from China claim Kaletra/Aluvia (lopinavir/ritonavir) is effective in COVID-19 treatment.
-
March 06, 2020- MAVIRET now available in the EU as an 8-week treatment option for treatment-naïve, chronic hepatitis C (HCV) patients without cirrhosis or with compensated cirrhosis, regardless of genotype*
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
